FATE THERAPEUTICS INC

Based in San Diego, Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies targeting cancer and immune disorders. The company's pipeline centers on chimeric antigen receptor (CAR) technologies applied to natural killer cells, T cells, and induced pluripotent stem cell (iPSC)-derived platforms. Key programs include FT522 for B-cell lymphoma and autoimmunity, FT819 for systemic lupus erythematosus, FT839 for complex autoimmune diseases, and FT825 for solid tumors, with FT836 remaining in preclinical development. The company also maintains a collaboration and option agreement with Ono Pharmaceutical for off-the-shelf, iPSC-derived CAR T-cell candidates targeting solid tumors.

The company generates revenue primarily through research collaborations and licensing agreements rather than product sales, as its candidates remain in preclinical and early clinical stages. The Ono Pharmaceutical partnership represents a significant component of the company's business model and funding structure. Fate Therapeutics operates internationally, with development activities spanning multiple geographies, though the company maintains its primary operations in the United States. As a clinical-stage enterprise with a market capitalization of approximately $0.2 billion, the company's scale reflects its pre-revenue status and position within the broader biotechnology sector focused on cellular immunotherapy.